{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:30Z","timestamp":1786982730088,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40122-020-00156-6","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T06:03:04Z","timestamp":1581487384000},"page":"261-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study"],"prefix":"10.1007","volume":"9","author":[{"given":"Masayuki","family":"Baba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kuroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Ohwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"issue":"3","key":"156_CR1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2337\/dc15-1536","volume":"39","author":"A Nanditha","year":"2016","unstructured":"Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. 2016;39(3):472\u201385.","journal-title":"Diabetes Care"},{"key":"156_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.diabres.2018.08.020","volume":"144","author":"G Sloan","year":"2018","unstructured":"Sloan G, Shillo P, Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabetes Res Clin Pract. 2018;144:177\u201391.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"156_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11892-019-1150-5","volume":"19","author":"P Shillo","year":"2019","unstructured":"Shillo P, Sloan G, Greig M, et al. Painful and painless diabetic neuropathies: what is the difference? Curr Diabetes Rep. 2019;19(6):32.","journal-title":"Curr Diabetes Rep"},{"issue":"3","key":"156_CR4","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.diabres.2013.12.003","volume":"103","author":"SS Kim","year":"2014","unstructured":"Kim SS, Won JC, Kwon HS, et al. Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: results from a nationwide hospital-based study of diabetic neuropathy in Korea. Diabetes Res Clin Pract. 2014;103(3):522\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"156_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.dsx.2017.09.013","volume":"12","author":"YW Pai","year":"2018","unstructured":"Pai YW, Lin CH, Lee IT, Chang MH. Prevalence and biochemical risk factors of diabetic peripheral neuropathy with or without neuropathic pain in Taiwanese adults with type 2 diabetes mellitus. Diabetes Metab Syndr. 2018;12(2):111\u20136.","journal-title":"Diabetes Metab Syndr"},{"key":"156_CR6","first-page":"318352","volume":"2013","author":"M Tsuji","year":"2013","unstructured":"Tsuji M, Yasuda T, Kaneto H, et al. Painful diabetic neuropathy in Japanese diabetic patients is common but underrecognized. Pain Res Treat. 2013;2013:318352.","journal-title":"Pain Res Treat"},{"issue":"6","key":"156_CR7","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s12325-017-0536-5","volume":"34","author":"RA Malik","year":"2017","unstructured":"Malik RA, Aldinc E, Chan SP, et al. Perceptions of painful diabetic peripheral neuropathy in South-East Asia: results from patient and physician surveys. Adv Ther. 2017;34(6):1426\u201337.","journal-title":"Adv Ther"},{"issue":"261","key":"156_CR8","first-page":"23","volume":"2017","author":"P Paisley","year":"1802","unstructured":"Paisley P, Serpell M. Improving pain control in diabetic neuropathy. Practitioner. 1802;2017(261):23\u20136.","journal-title":"Practitioner"},{"issue":"10","key":"156_CR9","doi-asserted-by":"publisher","first-page":"e0187250","DOI":"10.1371\/journal.pone.0187250","volume":"12","author":"N Ebata-Kogure","year":"2017","unstructured":"Ebata-Kogure N, Nozawa K, Murakami A, et al. Clinical and economic burdens experienced by patients with painful diabetic peripheral neuropathy: an observational study using a Japanese claims database. PLoS One. 2017;12(10):e0187250.","journal-title":"PLoS One"},{"issue":"6","key":"156_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/1479164116653240","volume":"13","author":"C D\u2019Amato","year":"2016","unstructured":"D\u2019Amato C, Morganti R, Greco C, et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diabetes Vasc Dis Res. 2016;13(6):418\u201328.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"6","key":"156_CR11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.clinthera.2018.04.001","volume":"40","author":"Z Iqbal","year":"2018","unstructured":"Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828\u201349.","journal-title":"Clin Ther"},{"key":"156_CR12","unstructured":"Eli Lilly and Company I, IN, USA. Cymbalta (duloxetine) prescribing information. https:\/\/pi.lilly.com\/us\/cymbalta-pi.pdf; 2017."},{"key":"156_CR13","unstructured":"Pfizer Inc. NY, NY, USA. Lyrica (pregabalin) prescribing information. http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=561; 2019."},{"issue":"11","key":"156_CR14","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/pme.12845","volume":"16","author":"M Yang","year":"2015","unstructured":"Yang M, Qian C, Liu Y. Suboptimal treatment of diabetic peripheral neuropathic pain in the United States. Pain Med. 2015;16(11):2075\u201383.","journal-title":"Pain Med"},{"issue":"1","key":"156_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13300-018-0550-x","volume":"10","author":"S Azmi","year":"2019","unstructured":"Azmi S, ElHadd KT, Nelson A, et al. Pregabalin in the management of painful diabetic neuropathy: a narrative review. Diabetes Ther. 2019;10(1):35\u201356.","journal-title":"Diabetes Ther"},{"issue":"20","key":"156_CR16","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1212\/WNL.0000000000003882","volume":"88","author":"JM Waldfogel","year":"2017","unstructured":"Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology. 2017;88(20):1958\u201367.","journal-title":"Neurology"},{"key":"156_CR17","first-page":"1","volume":"17","author":"S Amato Nesbit","year":"2018","unstructured":"Amato Nesbit S, Sharma R, Waldfogel JM, et al. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Curr Med Res Opin. 2018;17:1\u201311.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"156_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01070-8","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Mirogabalin: first global approval. Drugs. 2019;79(4):463\u20138.","journal-title":"Drugs"},{"issue":"5","key":"156_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/j.pain.0000000000001501","volume":"160","author":"J Kato","year":"2019","unstructured":"Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain. 2019;160(5):1175\u201385.","journal-title":"Pain"},{"key":"156_CR20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/jdi.13013","volume":"10","author":"M Baba","year":"2019","unstructured":"Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig. 2019;10:1299\u2013306.","journal-title":"J Diabetes Investig"},{"issue":"3","key":"156_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1124\/jpet.117.247551","volume":"365","author":"Y Domon","year":"2018","unstructured":"Domon Y, Arakawa N, Inoue T, et al. Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the alpha2delta subunit of voltage-gated calcium channels. J Pharmacol Exp Ther. 2018;365(3):573\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"156_CR22","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1021\/jm060650z","volume":"50","author":"MJ Field","year":"2007","unstructured":"Field MJ, Li Z, Schwarz JB. Ca2\u2009+\u2009channel alpha2-delta ligands for the treatment of neuropathic pain. J Med Chem. 2007;50(11):2569\u201375.","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"156_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pain.2006.04.022","volume":"125","author":"CY Li","year":"2006","unstructured":"Li CY, Zhang XL, Matthews EA, et al. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain. 2006;125(1\u20132):20\u201334.","journal-title":"Pain"},{"issue":"11","key":"156_CR24","first-page":"659","volume":"73","author":"Y Domon","year":"2018","unstructured":"Domon Y, Kitano Y, Makino M. Analgesic effects of the novel alpha(2)delta ligand mirogabalin in a rat model of spinal cord injury. Pharmazie. 2018;73(11):659\u201361.","journal-title":"Pharmazie"},{"issue":"6","key":"156_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cpdd.448","volume":"7","author":"M Jansen","year":"2018","unstructured":"Jansen M, Warrington S, Dishy V, et al. A randomized, placebo-controlled, double-blind study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated doses of mirogabalin in healthy Asian volunteers. Clin Pharmacol Drug Dev. 2018;7(6):661\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"156_CR26","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.2337\/dc14-1044","volume":"37","author":"A Vinik","year":"2014","unstructured":"Vinik A, Rosenstock J, Sharma U, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37(12):3253\u201361.","journal-title":"Diabetes Care"},{"issue":"12","key":"156_CR27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"156_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","volume":"30","author":"R Melzack","year":"1987","unstructured":"Melzack R. The short-form McGill pain questionnaire. Pain. 1987;30(2):191\u20137.","journal-title":"Pain"},{"key":"156_CR29","volume-title":"Handbook of psychiatric measures","author":"W Guy","year":"2000","unstructured":"Guy W. Clinical global impressions (CGI) scale, modified. In: Rush JA, editor. Handbook of psychiatric measures. 1st ed. Washington: American Psychiatric Association; 2000.","edition":"1"},{"issue":"11","key":"156_CR30","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1097\/j.pain.0000000000001340","volume":"159","author":"NB Finnerup","year":"2018","unstructured":"Finnerup NB, Haroutounian S, Baron R, et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain. 2018;159(11):2339\u201346.","journal-title":"Pain"},{"issue":"11","key":"156_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/17512433.2016.1240029","volume":"9","author":"I Gilron","year":"2016","unstructured":"Gilron I. Methodological issues associated with clinical trials in neuropathic pain. Expert Rev Clin Pharmacol. 2016;9(11):1399\u2013402.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"156_CR32","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","volume":"156","author":"AH Tuttle","year":"2015","unstructured":"Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in US clinical trials of neuropathic pain. Pain. 2015;156(12):2616\u201326.","journal-title":"Pain"},{"issue":"5","key":"156_CR33","doi-asserted-by":"publisher","first-page":"e00418","DOI":"10.1002\/prp2.418","volume":"6","author":"K Brown","year":"2018","unstructured":"Brown K, Mendell J, Ohwada S, et al. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: results from phase 1 studies. Pharmacol Res Perspect. 2018;6(5):e00418.","journal-title":"Pharmacol Res Perspect"},{"issue":"Suppl 1","key":"156_CR34","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1097\/j.pain.0000000000000445","volume":"157","author":"L Vase","year":"2016","unstructured":"Vase L, Skyt I, Hall KT. Placebo, nocebo, and neuropathic pain. Pain. 2016;157(Suppl 1):S98\u2013105.","journal-title":"Pain"},{"issue":"1","key":"156_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","volume":"28","author":"J Satoh","year":"2011","unstructured":"Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14\u00a0week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1):109\u201316.","journal-title":"Diabet Med"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-020-00156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-020-00156-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-020-00156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T12:06:37Z","timestamp":1718798797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-020-00156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s40122-020-00156-6","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"19 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}